New antibody aims to control lymphoma without chemo side effects

NCT ID NCT03322865

First seen May 13, 2026 · Last updated May 16, 2026 · Updated 2 times

Summary

This study tests a drug called obinutuzumab in 56 people with newly diagnosed marginal zone lymphoma who cannot have or did not respond to local therapy. The goal is to see if this antibody can shrink tumors and control the disease without the harsh side effects of chemotherapy. Participants receive the drug alone, and doctors check how many achieve complete remission after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Augusta-Kranken-Anstalt gGmbH

    Bochum, 44791, Germany

  • Gemeinschaftspraxis für Hämatologie und Onkologie

    Münster, 48149, Germany

  • Institut für Versorgungsforschung GbR

    Koblenz, 56068, Germany

  • Klinikum Passau

    Passau, 94032, Germany

  • University Hospital Essen

    Essen, 45147, Germany

  • University Hospital Halle

    Halle, 06120, Germany

  • University Hospital Mainz

    Mainz, 55101, Germany

  • University Hospital Münster

    Münster, 48149, Germany

  • University Hospital Ulm

    Ulm, 89081, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, 79106, Germany

  • Universitätsklinikum Mannheim

    Mannheim, 68167, Germany

  • Universitätsmedizin Georg-August-University

    Göttingen, 37075, Germany

Conditions

Explore the condition pages connected to this study.